- Home
- About Us
- Divisions
- Adolescent and Young Adult Medicine
- Allergy and Immunology
- Blood and Marrow Transplantation and Cellular Therapies
- Cardiology
- Child Advocacy
- Emergency Medicine
- Endocrinology
- Gastroenterology, Hepatology and Nutrition
- General Academic Pediatrics
- Genetic and Genomic Medicine
- Health Informatics
- Hematology-Oncology
- Infectious Diseases
- Nephrology
- Neurology and Child Development
- Newborn Medicine
- Paul C. Gaffney Division of Pediatric Hospital Medicine
- Pulmonology
- Rheumatology
- Centers & Institutes
- Center for Pediatric Research in Obesity and Metabolism
- Center for Rare Disease Therapy
- Children's Center for Neurogenomics
- Children's Neuroscience Institute
- Cystic Fibrosis Research Center
- Institute for Infection, Inflammation, and Immunity in Children
- Pediatric Asthma Center
- Pediatric Institute for Heart Regeneration and Therapeutics
- Richard King Mellon Foundation Institute for Pediatric Research
- Pittsburgh Vaccine Trials Unit
- The Pittsburgh Study
- Research
- Diversity
- Education
- Faculty Affairs
- News
- People
- Podcasts
Torok Lab
Video provided by UPMC Physician Journal, the Emmy-nominated digital program produced out of UPMC's Digital Marketing department.
Dr. Kathryn S. Torok's laboratory conducts multiple juvenile scleroderma clinical and translational research studies, including hosting the National RegiChildhood-Onsetood Onset Scleroderma (NRCOS) at the University of Pittsburgh. The lab's primary areas of focus include discovery of juvenile scleroderma immunophenotypes and biomarker development, genomic analyses to determine genetic links to disease activity and progression, and development and validation of outcome measures in pediatric scleroderma. These themes are both interwoven and complementary to achieve our research team’s overall goal of providing better care for patients with pediatric-onset scleroderma.
Pediatric localized scleroderma (LS) and systemic sclerosis (SSc) are disfiguring autoimmune diseases of the skin and underlying tissues. Smoldering disease activity leads to fibrosis and atrophy, causing physical and psychological disability that continues throughout childhood into adulthood. Available therapies for LS and SSc are variably effective and are associated with morbidity themselves. A better understanding of the pathophysiology of LS and SSc, especially during the active inflammatory phase, would lead toward more targeted and effective therapies. Our lab uses multiple approaches to increase understanding of LS and SSc, including disease immunophenotyping, genomic analyses, and quality of life measures.
Affiliated Faculty and Staff
- Kathryn Seraphin Torok, MD - Principal Investigator
- Kaila Schollaert-Fitch, MA - Clinical Research Coordinator
- Emily Mirizio, BS - Lab Technician
- Aly Boucher - Undergraduate Student
- Shalini Jose - Undergraduate Student
- Christopher Liu - Undergraduate Student